Laélia Briand Madrid1, Stéphane Morel2, Khadim Ndiaye3, Salim Mezaache4, Daniela Rojas Castro5, Marion Mora6, Fabrice Olivet7, Virginie Laporte8, Camelia Protopopescu9, Patrizia Carrieri10, Perrine Roux11. 1. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: laelia.briand-madrid@inserm.fr. 2. AIDES, 14 Rue Scandicci, 93508 Pantin, France. Electronic address: smorel@aides.org. 3. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: khadim.ndiaye@inserm.fr. 4. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: salim.mezaache@inserm.fr. 5. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; AIDES, 14 Rue Scandicci, 93508 Pantin, France; Groupe de Recherche en Psychologie Sociale (EA 4163), Université Lyon 2, 5 Avenue Pierre Mendès France, 69676 Bron, France; Coalition Plus, 14 Rue Scandicci, 93508 Pantin, France. Electronic address: drojas@aides.org. 6. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: marion.mora@inserm.fr. 7. ASUD, 32 Rue Vitruve, 75020 Paris, France. Electronic address: contact@asud.org. 8. AIDES, 14 Rue Scandicci, 93508 Pantin, France. Electronic address: vlaporte@aides.org. 9. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: camelia.protopopescu@inserm.fr. 10. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: pmcarrieri@aol.com. 11. Aix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, Faculté de médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Faculté de Médecine, 27 Boulevard Jean Moulin, 13385 Marseille, France. Electronic address: perrine.roux@inserm.fr.
Abstract
BACKGROUND: Regular consumption of opioids exposes individuals to several side effects. One of these is a loss of libido, which has a negative impact on quality of life. We used a cross-sectional community-based survey of people who inject opioids to study factors associated with loss of libido, and more particularly the impact of the type of opioid injected. METHODS: This secondary study was conducted throughout France in 2015 and involved 514 people who inject opioids. Self-reported sociodemographic characteristics, drug consumption, injection-related data and loss of libido were collected using a brief questionnaire administered either through face-to-face interviews or online. Two different models were used to identify factors associated with loss of libido: simple logistic regression and a two-step Heckman model. RESULTS: Forty-three percent of the participants reported a loss of libido. The first model showed that filling in the questionnaire online (OR[95%CI] = 2.55[1.64;3.96]; p < 0.001), reporting that morphine sulfate (OR[95%CI] = 2.67[1.56;4.58]; p < 0.001) or methadone (OR[95%CI] = 2.50[1.13;5.56]; p = 0.030) was the opioid they injected most (versus buprenorphine), and reporting benzodiazepine use (OR[95%CI] = 1.62[1.07;2.44]; p = 0.033) were factors strongly associated with loss of libido. In the two-step, Heckman model which corrected for selection bias, along with these factors, reporting heroin as the opioid injected most was also strongly associated. CONCLUSION: Our findings showed that full-opioid agonists could have a negative impact on libido when injected regularly. Libido can improve quality of life and should be routinely discussed through counseling in prevention services with people who inject drugs.
BACKGROUND: Regular consumption of opioids exposes individuals to several side effects. One of these is a loss of libido, which has a negative impact on quality of life. We used a cross-sectional community-based survey of people who inject opioids to study factors associated with loss of libido, and more particularly the impact of the type of opioid injected. METHODS: This secondary study was conducted throughout France in 2015 and involved 514 people who inject opioids. Self-reported sociodemographic characteristics, drug consumption, injection-related data and loss of libido were collected using a brief questionnaire administered either through face-to-face interviews or online. Two different models were used to identify factors associated with loss of libido: simple logistic regression and a two-step Heckman model. RESULTS: Forty-three percent of the participants reported a loss of libido. The first model showed that filling in the questionnaire online (OR[95%CI] = 2.55[1.64;3.96]; p < 0.001), reporting that morphine sulfate (OR[95%CI] = 2.67[1.56;4.58]; p < 0.001) or methadone (OR[95%CI] = 2.50[1.13;5.56]; p = 0.030) was the opioid they injected most (versus buprenorphine), and reporting benzodiazepine use (OR[95%CI] = 1.62[1.07;2.44]; p = 0.033) were factors strongly associated with loss of libido. In the two-step, Heckman model which corrected for selection bias, along with these factors, reporting heroin as the opioid injected most was also strongly associated. CONCLUSION: Our findings showed that full-opioid agonists could have a negative impact on libido when injected regularly. Libido can improve quality of life and should be routinely discussed through counseling in prevention services with people who inject drugs.
Authors: Andrew Scheibe; Katherine Young; Lorraine Moses; Rudolph L Basson; Anna Versfeld; C Wendy Spearman; Mark W Sonderup; Nishi Prabdial-Sing; Jack Manamela; Adrian J Puren; Kevin Rebe; Harry Hausler Journal: Harm Reduct J Date: 2019-04-11